A review of clinical aspects of breast cancer

被引:149
作者
Libson, Shai [1 ]
Lippman, Marc [2 ]
机构
[1] Ben Gurion Univ Negev, Soroka Med Ctr, IL-84105 Beer Sheva, Israel
[2] Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA
关键词
RADIOTHERAPY HYPOFRACTIONATION; RANDOMIZED MULTICENTER; ADJUVANT CHEMOTHERAPY; POSTMENOPAUSAL WOMEN; RADICAL-MASTECTOMY; UK STANDARDIZATION; LOCAL RECURRENCE; DUCTAL CARCINOMA; OPEN-LABEL; FOLLOW-UP;
D O I
10.3109/09540261.2013.852971
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Breast cancer is the most frequently diagnosed cancer in women and ranks second among causes for cancer related death in women. The ability to identify and diagnose breast cancer has improved markedly. Treatment decisions which were based in the past predominantly on the anatomic extent of the disease are shifting to the underlying biological mechanisms. Gene array technology has led to the recognition that breast cancer is a heterogeneous disease composed of different biological subtypes, and genetic profiling enables response to chemotherapy to be predicted. Breast conservation became an established standard of care and the oncoplastic approach enables wide excisions without compromising the natural shape of the breast. Sentinel lymph node biopsy has replaced axillary dissection as the standard procedure to stage the axilla and spared many patients the excess morbidity of axillary dissection. Targeted therapy to the oestrogen receptor plays a major role in systemic therapy; pathways responsible for endocrine resistance have been targeted as well. Biological therapy has been developed to target HER2 receptor and combination of antibody drug conjugates linked cytotoxic therapy to HER2 antibodies. Meaningful improvements in survival resulted from the new effective systemic agents and patients with metastasis are likely to have a longer survival.
引用
收藏
页码:4 / 15
页数:12
相关论文
共 62 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]  
Aebi S., 2012, SAN ANT BREAST CANC
[3]   Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [J].
Albain, K. ;
Anderson, S. ;
Arriagada, R. ;
Barlow, W. ;
Bergh, J. ;
Bliss, J. ;
Buyse, M. ;
Cameron, D. ;
Carrasco, E. ;
Clarke, M. ;
Correa, C. ;
Coates, A. ;
Collins, R. ;
Costantino, J. ;
Cutter, D. ;
Cuzick, J. ;
Darby, S. ;
Davidson, N. ;
Davies, C. ;
Davies, K. ;
Delmestri, A. ;
Di Leo, A. ;
Dowsett, M. ;
Elphinstone, P. ;
Evans, V. ;
Ewertz, M. ;
Gelber, R. ;
Gettins, L. ;
Geyer, C. ;
Goldhirsch, A. ;
Godwin, J. ;
Gray, R. ;
Gregory, C. ;
Hayes, D. ;
Hill, C. ;
Ingle, J. ;
Jakesz, R. ;
James, S. ;
Kaufmann, M. ;
Kerr, A. ;
MacKinnon, E. ;
McGale, P. ;
McHugh, T. ;
Norton, L. ;
Ohashi, Y. ;
Paik, S. ;
Pan, H. C. ;
Perez, E. ;
Peto, R. ;
Piccart, M. .
LANCET, 2012, 379 (9814) :432-444
[4]   Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial [J].
Anderson, Garnet L. ;
Chlebowski, Rowan T. ;
Aragaki, Aaron K. ;
Kuller, Lewis H. ;
Manson, JoAnn E. ;
Gass, Margery ;
Bluhm, Elizabeth ;
Connelly, Stephanie ;
Hubbell, F. Allan ;
Lane, Dorothy ;
Martin, Lisa ;
Ockene, Judith ;
Rohan, Thomas ;
Schenken, Robert ;
Wactawski-Wende, Jean .
LANCET ONCOLOGY, 2012, 13 (05) :476-486
[5]  
[Anonymous], 2005, LANCET
[6]   Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation:: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics [J].
Antoniou, A. C. ;
Hardy, R. ;
Walker, L. ;
Evans, D. G. ;
Shenton, A. ;
Eeles, R. ;
Shanley, S. ;
Pichert, G. ;
Izatt, L. ;
Rose, S. ;
Douglas, F. ;
Eccles, D. ;
Morrison, P. J. ;
Scott, J. ;
Zimmern, R. L. ;
Easton, D. F. ;
Pharoah, P. D. P. .
JOURNAL OF MEDICAL GENETICS, 2008, 45 (07) :425-431
[7]   Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study [J].
Bachelot, Thomas ;
Bourgier, Celine ;
Cropet, Claire ;
Ray-Coquard, Isabelle ;
Ferrero, Jean-Marc ;
Freyer, Gilles ;
Abadie-Lacourtoisie, Sophie ;
Eymard, Jean-Christophe ;
Debled, Marc ;
Spaeth, Dominique ;
Legouffe, Eric ;
Allouache, Djelila ;
El Kouri, Claude ;
Pujade-Lauraine, Eric .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) :2718-2724
[8]   Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].
Baselga, Jose ;
Bradbury, Ian ;
Eidtmann, Holger ;
Di Cosimo, Serena ;
de Azambuja, Evandro ;
Aura, Claudia ;
Gomez, Henry ;
Dinh, Phuong ;
Fauria, Karine ;
Van Dooren, Veerle ;
Aktan, Gursel ;
Goldhirsch, Aron ;
Chang, Tsai-Wang ;
Horvath, Zsolt ;
Coccia-Portugal, Maria ;
Domont, Julien ;
Tseng, Ling-Min ;
Kunz, Georg ;
Sohn, Joo Hyuk ;
Semiglazov, Vladimir ;
Lerzo, Guillermo ;
Palacova, Marketa ;
Probachai, Volodymyr ;
Pusztai, Lajos ;
Untch, Michael ;
Gelber, Richard D. ;
Piccart-Gebhart, Martine .
LANCET, 2012, 379 (9816) :633-640
[9]   Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].
Baselga, Jose ;
Cortes, Javier ;
Kim, Sung-Bae ;
Im, Seock-Ah ;
Hegg, Roberto ;
Im, Young-Hyuck ;
Roman, Laslo ;
Pedrini, Jose Luiz ;
Pienkowski, Tadeusz ;
Knott, Adam ;
Clark, Emma ;
Benyunes, Mark C. ;
Ross, Graham ;
Swain, Sandra M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119
[10]  
Beaver JA, 2012, FUTURE ONCOL, V8, P651, DOI [10.2217/FON.12.49, 10.2217/fon.12.49]